SINGULAIR (montelukast sodium) by Merck & Co. is leukotriene receptor antagonists [moa]. First approved in 2002.
Drug data last refreshed 16h ago · AI intelligence enriched 19h ago
SINGULAIR (montelukast sodium) is an oral leukotriene receptor antagonist indicated for asthma and allergic rhinitis. It works by blocking cysteinyl leukotriene receptors, reducing airway inflammation and bronchoconstriction. The granule formulation enables dosing in pediatric and patients with swallowing difficulties.
Mature product approaching loss of exclusivity with minimal Part D volume, signaling a small, consolidating brand team focused on managed decline and generic transition.
Leukotriene Receptor Antagonists
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence Study of Montelukast Sodium Oral Thin Film and Chewable Tablet in Fasted Healthy Volunteers
Bioequivalence Study of Montelukast Sodium Oral Thin Film and Chewable Tablet in Fed Healthy Volunteers
Relative Bioavailability Study of Two Montelukast Sodium (GW483100) 5 Milligrams (mg) Chewable Tablets and One Reference Montelukast Sodium 5 mg Chewable Tablet in Healthy Adult Subjects
A Bioequivalence Study of Montelukast From Asmakast 10mg Tabs (Sandoz, Egypt) & Singulair 10mg Tabs (Merck)
Bioequivalence Study of Montelukast From Asmakast 5mg Chewable Tab.(Sandoz, Egypt) & Singulair 5mg Chewable Tab.(Merck)
Worked on SINGULAIR at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on SINGULAIR offers limited career growth given its LOE status and minimal linked job openings. Positions focus on managing stakeholder relationships, optimizing reimbursement, and supporting existing patients rather than building new commercial infrastructure.